A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Registrational; Therapeutic Use
- Acronyms REGENERATE
- Sponsors Intercept Pharmaceuticals
- 04 May 2017 According to an Intercept Pharmaceuticals media release, enrollment of interim analysis cohort has been completed.
- 23 Feb 2017 According to an Intercept Pharmaceuticals media release, the company expects to complete the enrollment of the interim analysis cohort in this trial by mid-2017.
- 19 Oct 2016 Trial design presented at the 81st Annual Scientific Meeting of the American College of Gastroenterology